ANODAN-PLUS OINTMENT 0.5 % — DIN 02453185
ZINC SULFATE : 0.5 % PRAMOXINE HYDROCHLORIDE : 1 % · ODAN LABORATORIES LTD · OINTMENT · wholesale supply in Canada
Health Canada status: APPROVED
What is ANODAN-PLUS OINTMENT?
ANODAN-PLUS OINTMENT 0.5 % contains ZINC SULFATE : 0.5 % PRAMOXINE HYDROCHLORIDE : 1 %. It is listed in the Health Canada Drug Product Database under DIN 02453185, held by ODAN LABORATORIES LTD, supplied as OINTMENT for RECTAL administration. Health Canada currently lists it as approved, status dated 15-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
Is there a generic Pramocaine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Pramocaine, across 11 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| CHURCH & DWIGHT CANADA CORP | 2 | 2 | ANUSOL PLUS OINTMENT, ANUSOL PLUS SUPPOSITORIES | Sourceable in Canada |
| ODAN LABORATORIES LTD | 2 | 0 | ANODAN-PLUS, ANODAN-PLUS OINTMENT | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | HEMORRHOIDAL OINTMENT | No marketed DIN |
| ABBOTT LABORATORIES, LIMITED | 1 | 0 | TRONOTHANE PRAMOXINE HCL CRM 1% USP | No marketed DIN |
| JAMP PHARMA CORPORATION | 1 | 0 | HEMORRHOID OINTMENT | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | SANDOZ ANUZINC PLUS | No marketed DIN |
| STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | 1 | 0 | HEMORRHOID OINTMENT | No marketed DIN |
| WARNER-LAMBERT CANADA INC. | 1 | 0 | W15883-CS | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.5 % |
|---|---|
| Dosage form | OINTMENT |
| Route | RECTAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Pramocaine |
|---|---|
| ATC code | C05AD07 |
| AHFS class | 84:08.00 ; 52:04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02453185 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2453185 |
| Brand name | ANODAN-PLUS OINTMENT |
| Generic / active ingredient | ZINC SULFATE : 0.5 % PRAMOXINE HYDROCHLORIDE : 1 % |
| Market authorization holder | ODAN LABORATORIES LTD |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | C05AD07 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C05AD |
| Current status | APPROVED |
| Status date | 15-Mar-2016 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANUSOL PLUS OINTMENT | 0.5 % | OINTMENT | CHURCH & DWIGHT CANADA CORP | MARKETED | 01945912 |
| ANUSOL PLUS SUPPOSITORIES | 20 MG | SUPPOSITORY | CHURCH & DWIGHT CANADA CORP | MARKETED | 01945904 |
| ANODAN-PLUS | 20 MG | SUPPOSITORY | ODAN LABORATORIES LTD | APPROVED | 02450801 |
| HEMORRHOID OINTMENT | 1 % | OINTMENT | STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | CANCELLED POST MARKET | 02229647 |
| HEMORRHOID OINTMENT | 0.5 % | OINTMENT | JAMP PHARMA CORPORATION | DORMANT | 02251981 |
| HEMORRHOIDAL OINTMENT | 0.5 % | OINTMENT | PHARMASCIENCE INC | CANCELLED POST MARKET | 02248891 |
| HEMORRHOIDAL OINTMENT | 0.5 % | OINTMENT | PHARMASCIENCE INC | CANCELLED POST MARKET | 02218887 |
| SANDOZ ANUZINC PLUS | 10 MG | OINTMENT | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02248424 |
| TRONOTHANE PRAMOXINE HCL CRM 1% USP | 1 % | CREAM | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | 01963104 |
| W15883-CS | 1 % | OINTMENT | WARNER-LAMBERT CANADA INC. | CANCELLED PRE MARKET | 02240584 |
2 · Same class — other molecules in ATC C05AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pramocaine | ANODAN-PLUS · ANODAN-PLUS OINTMENT · ANUSOL PLUS OINTMENT · ANUSOL PLUS SUPPOSITORIES · +5 more | 11 | 2 | Yes |
| Lidocaine | SEAFORD NIFEDIPINE AND LIDOCAINE HYDROCHLORIDE CREAM · TOPICAINE 5 | 2 | 1 | Yes |
| Benzocaine | ANAL SWABS 20% · HEMORRO-DOL ONT · HEMORRO-DOL SUP · ONRECTAL · +2 more | 6 | 0 | Not in Canada |
| Pramocaine, Combinations | ANUZINC PLUS SUPPOSITORIES · HEMORRHOIDAL OINTMENT WITH ANESTHETIC FOR EXTRA PAIN RELIEF | 2 | 0 | Not in Canada |
| Anesthetics, Combinations | POMMADE MIDY | 1 | 0 | Not in Canada |
| Cinchocaine | NUPERCAINAL ANESTHETIC OINTMENT 1% | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C05AA | Hydrocortisone · Hydrocortisone, Combinations | 37 | 10 |
| C05AX | Other Agents For Treatment Of Hemorrhoids And Anal Fissures For Topical Use · Other Preparations, Combinations · Zinc Preparations | 20 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.